Jan 13, 2020
RESEARCH TRIANGLE PARK – Morrisville-based Locus Biosciences, a developer of precision antibacterial therapies, will conduct the world’s first clinical trial of a recombinant bacteriophage therapy, a major milestone for the field, the…
Jul 19, 2018
Locus Biosciences Inc., an emerging biotechnology company developing CRISPR-Cas3-engineered precision antibacterial products, announced today its acquisition of EpiBiome, Inc.’s high-throughput bacteriophage (“phage”) discovery platform. Pairing EpiBiome’s powerful phage isolation and…
Jan 19, 2018
Dr. Rodolphe Barrangou, the Todd R. Klaenhammer Distinguished Scholar in Probiotics Research, University Scholar and associate professor in the NC State Department of Food, Bioprocessing and Nutrition Sciences, will receive the 2018 NAS…
Nov 15, 2017
Locus Biosciences, born with the help of two loans from the North Carolina Biotechnology Center, has raised $19 million in Series A funding from major investors. The round was led…
Jul 17, 2017
Research Triangle Park-based Locus Biosciences has secured a $5 million convertible note. Chinese technology giant Tencent Holdings Limited led the financing round, which also included the N.C. Biotechnology Center. One…
Oct 27, 2016
While Crispr-Cas9 has drawn a lot of attention, scientists are investigating other Crispr approaches that may reach doctors and patients more quickly.